California is currently home to 5585 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Recruiting
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 pa... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
11/18/2024
Locations: UCLA Doheny Eye Center /ID# 227587, Pasadena, California
Conditions: Open-Angle Glaucoma
Combined Transcranial Magnetic Stimulation and Therapy for MTBI Related Headaches
Recruiting
This study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rTMS) and telehealth based therapy in helping manage mild traumatic brain injury (mTBI) related headaches. The investigators hypothesize that active rTMS combined with telehealth therapy will provide marked reduction in mTBI related headaches and symptoms in comparison to their placebo counterparts.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/18/2024
Locations: VA San Diego Healthcare System, San Diego, California
Conditions: TBI (Traumatic Brain Injury), Headache, Depression
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Recruiting
Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings. Obstructive sleep apnea (OSA) is highly comorbid with both disorders and untreated OSA is associated with worse functional impairment across multiple domains, worse qualit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: VA San Diego Healthcare System, San Diego, CA, San Diego, California
Conditions: Post Traumatic Stress Disorder, Obstructive Sleep Apnea, Substance Use Disorder, Residential Treatment Program
Trans-abdominal Fetal Pulse Oximetry; Tissue Light Scattering and Signal Integrity
Recruiting
The overall purpose of this study is to evaluate maternal-fetal tissue light scattering properties. The objectives of the study are: (i) integrate established mathematical principles of oxygen saturation to model with increasing accuracy the "body in a body" problem of fetus in mother; similar to existing pulse oximeters, the calculations will be integrated into software in the final commercial product; (ii) obtain human measurements against which both computational models and animal data can be... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Yaron Friedman, MD, Inc., Walnut Creek, California
Conditions: Fetal Hypoxia
Imaging of Solid Tumors Using FAP-2286
Recruiting
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Solid Tumors, Adult, Metastatic Cancer
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: City of Hope cancer Center, Duarte, California
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Recruiting
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: UCSD, La Jolla, California
Conditions: Mucositis, Nephrotoxicity, Ototoxicity
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: University of California, Irvine, Irvine, California
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Coenzyme Q10 for Gulf War Illness: A Replication Study
Recruiting
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/15/2024
Locations: UC San Diego, La Jolla, California
Conditions: Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorder, Respiratory Chain
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
Recruiting
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.
Gender:
MALE
Ages:
80 years and below
Trial Updated:
11/15/2024
Locations: San Diego Clinical Trials, La Mesa, California
Conditions: Benign Prostatic Hyperplasia, Localized Prostate Cancer
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Castration-resistant prostate cancer continues to grow and spread despite the surgical removal... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Recruiting
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: City of Hope, Duarte, California
Conditions: Solid Tumor